Hayder Hatem Abdulwahhab

University of Çankırı Karatekin Department of Biology , Molecular biology

The paper aims to develop a new concept for stratifying cancer patients using their biomarker profiles. The study leading to HCC only assessed the diagnostic aspect of recurrent cancer. However, the next clinical evaluations will be geared towards predicting recurrence. Thus, the finalized platform should make it possible to determine marker profiles in a clinical context and to develop a set of rules for predicting the progression of the pathology, more particularly of recurrence. Such a predictive tool would be beneficial for the management of patients with bladder cancer. Indeed, the latter has a high rate of recurrence and improving the determination of the risk of recurrence would allow optimal and personalized care for each patient (Ahram M, 2008). Finally, this concept of personalized medicine thanks to the information obtained by the analysis of several parameters on our platform can be applied to other cancers or pathologies.Individual markers could play a role important diagnostic or predictive, and this clinical utility in the laboratories clinical automated manner. The arrays of CpG methylation islands have allowed the identification of new individual epigenetic profiles and candidates that are clinically and biologically relevant in the tumorigenesis and progression of cancer, with utility for the early detection of the disease (Burger M, 2013). The characterization of BDNF in tissue samples, urine and cell lines in an integrated way has allowed the identification of a new gene that is epigenetically silenced by methylation and that has clinical utility for the diagnosis and tumor stratification of patients with cancer. It is necessary to characterize other candidates identified both at the methylation and miRNA levels and to carry out complementary and independent validations to define markers that also allow early non-invasive detection (J.S. Ross, 2014).

1) Ahram M, Petricoin EF (2008) Proteomics discovery of disease biomarkers. Biomark Insights 3: 325– 333.

2) Biomarkers Definitions Working Group. (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89–95.

3) Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63: 234–241.

4) Cancer Genome Atlas Research Network, Comprehensive molecular characterization of uothelial bladder carcinoma, Nature, 507 (7492) (2014), pp. 315-322.

5) Edwards NJ, Oberti M, Thangudu RR, Cai S, McGarvey PB, Jacob S, Madhavan S, Ketchum KA (2015) The CPTAC Data Portal: A resource for cancer proteomics research. J Proteome Res 14: 2707–2713.

6) Gogalic S, Sauer U, Doppler S, Preininger C (2015) Bladder cancer biomarker array to detect aberrant levels of proteins in urine. The Analyst 140: 724–735.

7) J.S. Ross, K. Wang, R.N. Al-Rohil, T. Nazeer, C.E. Sheehan, G.A. Otto, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy, Mod Pathol, 27 (2) (2014), pp. 271-280.

Volume 05 Issue 07 July 2022

There is an Open Access article, distributed under the term of the Creative Commons Attribution – Non Commercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits remixing, adapting and building upon the work for non-commercial use, provided the original work is properly cited.